OR WAIT 15 SECS
29 September 2015 Raleigh, NC
In an effort to accelerate new vaccines to market, PRA Health Sciences (PRA) is pleased to announce its collaboration with Alliance for Multispecialty Research (AMR). This partnership paves the way for a smarter approach to vaccine studies that will allow studies to run more efficiently and effectively.
“This is an ideal collaboration,” said Frank Hijek, PRA Senior Vice President, Strategic Drug Development. “It combines the expertise of PRA, one of the world’s leading contract research organizations, and AMR one of the most effective clinical research site networks in the industry. Together, we can help sponsors get vaccines to the people who need them.”
PRA’s vaccine experience includes Phase I-Phase IV adult and pediatric studies involving nearly 213,000 study participants at more than 3,000 sites around the world. PRA has provided clinical development support for ten approved vaccines over the past five years. Additionally, PRA supports four of the five top vaccine manufacturers.
“Our partnership with PRA allows us to provide a simple approach to effective vaccine studies,” said AMR CEO Brenda Atchison. “Our respective expertise will allow us to make significant strides in implementing efficient solutions to smarter vaccine development.”
AMR provides clinical study services across a broad range of therapeutic areas and has a breadth of vaccine trial experience for a variety of vaccine indications, including several bioterrorism-related government sponsored programs. Combining AMR and PRA expertise will allow for successful support of small to mid-size vaccine trials and AMR’s outstanding 98% subject retention rate will help sponsors meet or exceed enrollment timelines.
The vaccine market has traditionally been pediatric, but the adult vaccine market continues to grow and is expected to nearly double by 2020. Many of the vaccines under development in the adult market segment focus on infectious diseases such as avian flu, malaria and hepatitis, as well as cancer treatment and prevention.
The collaboration between PRA and AMR will facilitate identification of appropriate patient populations for vaccine studies. This will reduce development times and help bring much needed vaccines to market sooner.
ABOUT PRA HEALTH SCIENCES
At PRA Health Sciences, providing innovative solutions for our clients is what we do. Side-by-side with our clients, we strive to move drug discovery forward, helping them to develop life-saving and life-improving drugs. PRA has more than 11,000 employees working in 80+ countries providing comprehensive clinical development services across all phases. From full service clinical development to the pioneering Embedded Solutions™ model, PRA provides a broad spectrum of solutions that meet the demands of a diverse marketplace. PRA has worked on 100+ marketed drugs across several therapeutic areas and conducted the pivotal or supportive trials that led to FDA and/or international regulatory approval of 50+ such drugs.
The Alliance for Multispecialty Research (AMR) is a unique network of independently owned, geographically diverse, and highly experienced Clinical Research Centers of Excellence. Chartered as a formal organization in 1994, AMR Centers of Excellence provide clinical trial services across a broad base of therapeutic areas to the pharmaceutical, biotechnology, nutrition and medical device industries. AMR is the proud recipient of the 2015 World Vaccine Congress’ Vaccines in Excellence (ViE) Award for “Best Clinical Trial Network